News
FULC
7.36
-1.87%
-0.14
Weekly Report: what happened at FULC last week (0408-0412)?
Weekly Report · 1d ago
Weekly Report: what happened at FULC last week (0401-0405)?
Weekly Report · 04/08 11:54
Weekly Report: what happened at FULC last week (0325-0329)?
Weekly Report · 04/01 11:51
Weekly Report: what happened at FULC last week (0318-0322)?
Weekly Report · 03/25 11:54
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics, Inc. Granted non-statutory stock options to Patrick Horn, M.D., the company’s newly appointed chief medical officer. The company is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare diseases.
Barchart · 03/22 15:30
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)
TipRanks · 03/19 05:50
Fulcrum Therapeutics appoints Patrick Horn as permanent Chief Medical Officer
Healthcare Fulcrum Therapeutics appoints Patrick Horn as permanent Chief Medical Officer. Horn's most recently served as the Chief medical officer at HemoShear Therapeutic. The interim Chief Medical officer, Iain Fraser, will remain on the company's executive leadership team.
Seeking Alpha · 03/18 12:02
Weekly Report: what happened at FULC last week (0311-0315)?
Weekly Report · 03/18 11:52
*Fulcrum Therapeutics: Horn Was Chief Medical Officer at Albireo Pharma >FULC
Dow Jones · 03/18 11:01
*Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
Dow Jones · 03/18 11:00
Press Release: Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D. As Chief Medical Officer. Dr. Horn is a seasoned executive with over 20 years of experience in the field of rare disease drug development. Fulcrum is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases. Interim chief medical officer, Iain Fraser, will be responsible for leading clinical development.
Dow Jones · 03/18 11:00
*Fulcrum Therapeutics: Interim Chief Medical Officer Iain Fraser Will Continue to Serve on Fulcrum's Executive Leadership Team as Senior Vice Pres of Early Development >FULC
Dow Jones · 03/18 11:00
Fulcrum Therapeutics Price Target Announced at $14.00/Share by RBC Capital
Dow Jones · 03/13 16:41
Fulcrum Therapeutics Initiated at Outperform by RBC Capital
Dow Jones · 03/13 16:41
RBC Capital Initiates Coverage On Fulcrum Therapeutics with Outperform Rating, Announces Price Target of $14
Benzinga · 03/13 16:31
Weekly Report: what happened at FULC last week (0304-0308)?
Weekly Report · 03/11 11:48
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
United Natural Foods shares dipped 15.2% to $12.61 on Wednesday. The company posted adjusted earnings of 7 cents per share in second-quarter. Rail Vision Ltd. Shares jumped 115.2%. Airship AI Holdings, Inc. Shares climbed 37.8% after gaining 200% on Tuesday.
Benzinga · 03/06 18:54
Fulcrum hits 52-week high as CEO buys shares
Seeking Alpha · 03/06 17:14
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
Shares of Box, Inc. Rose sharply after the company reported better-than-expected fourth-quarter results. The Dow Jones index gained more than 200 points on Wednesday. Other big U.S. Stocks recording gains included JD.com, Apple, Lyft and Facebook.
Benzinga · 03/06 16:45
Weekly Report: what happened at FULC last week (0226-0301)?
Weekly Report · 03/04 11:51
More
Webull provides a variety of real-time FULC stock news. You can receive the latest news about Fulcrum Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About FULC
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.